WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

To join this study, you need to be at least 40 years old and have been diagnosed with Idiopathic Pulmonary Fibrosis (IPF) within the last seven years. Your diagnosis needs to meet specific medical guidelines.

If you're already taking standard IPF medicines like pirfenidone or nintedanib, your dose must have been steady for at least 90 days before the study starts, and you must plan to continue that same dose. You can't be taking both medicines at once. If you stopped taking these medicines, it needs to have been at least 30 days before the study begins, and you can't plan to restart them during the study.

Your lung function will be checked; specifically, your Forced Vital Capacity (FVC) and Diffusion Capacity of the Lung for Carbon Monoxide (DLCO) need to be above certain levels. You must also be able to understand the study, give your written permission to take part, and be able to attend all the study appointments.

If you join the study, you'll be randomly chosen to receive either the new medicine MTX-463 or a placebo. You won't know which one you're getting, and neither will your study doctor. Both the medicine and the placebo are given as an 'IV infusion,' which means it's delivered directly into your vein.

You'll receive an infusion every four weeks for a total of five infusions, starting on 'Day 0' and ending around 'Week 16'. The study will last about 28 weeks in total. After your last infusion, you'll have an 'End of Treatment' visit after four weeks, and a final 'Safety Follow-Up' visit four weeks after that.

Throughout the study, you'll have regular check-ups where your lung function will be measured using tests like FVC and L-PF. Blood samples will also be taken at various times to check your safety, measure levels of WISP1 (proteins that can be involved in lung scarring), and see how your body handles the study medicine.